Key targets in fibrogenesis and their corresponding clinically tested drugs
| Target molecules | Agent (company) | ClinicalTrials.gov or JAPIC identifier |
| Galectin-3 | TD139 (Balecto Biotech) | NCT02257177 |
| Autotaxin | GLPG1690 (Galapagos NV) | NCT03711162 NCT03733444 |
| GPR84 | GLPG1205 (Galapagos NV) | NCT03725852 |
| GPR40 and GPR84 | PBI-4050 (ProMetic BioSciences, Inc.) | NCT02538536 |
| PDE, 5-LO, LT, phospholipase C and thromboxane A2 | Tripelukast (MediciNova) | NCT02503657 |
| Integrin αvβ6 | BG00011 (Biogen) | NCT03573505 |
| Pentraxin-2 | PRM-151 (Promedior, Inc.) | NCT02550873 |
| Rho-associated kinase 2 | KD025 (Kadmon Corporation, LLC) | NCT02688647 |
| Connective tissue growth factor | FG-3019 (FibroGen) | NCT01262001 |
| c-Jun N-terinal kinase | CC-90001 (Celgene) | NCT03142191 |
| Nrf2 | Bardoxolone methyl (Reata Pharmaceuticals) | NCT02036970 |
| Receptor for B-cell activating factor of the TNF family | VAY736 (Novartis) | NCT03287414 |
| Heat shock protein 47 | ND-L02-s0201 (Nitto BioPharma) | NCT03538301 |
| Somatostatin | Octreitude (Novartis Pharma) | NCT00463983 |
| VEGFR, MET, FMS and PDGFR | TAS-115 (Taiho Pharma) | JapicCTI-183898 |
PDE: phosphodiesterase; 5-LO: arachidonate 5-lipoxygenase; LT: leukotriene; TNF: tumour necrosis factor; VEGFR: vascular endothelial growth factor receptor; MET: hepatocyte growth factor receptor; FMS: Feline McDonough Sarcoma oncogene; PDGFR: platelet-derived growth factor receptor.